
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is positioned favorably due to its focus on developing innovative therapies for significant unmet medical needs in oncology and COVID-19, particularly through its promising drug pipeline, including Endoxifen for breast cancer and AT-H201 and AT-301 for COVID-19. The company’s current valuation is considered attractive, with a positive outlook supported by a net present value (NPV) analysis indicating substantial potential for appreciation from the current share price. Furthermore, the anticipation of achieving key clinical milestones and data is expected to act as a strong catalyst for stock performance, enhancing the overall investment appeal.
Bears say
Atossa Therapeutics Inc. reported a net loss of $8.4 million, equating to an earnings per share (EPS) of $(0.07), which was below both management and consensus estimates of $(0.06). The company faces significant risks, including liquidity challenges, potential failures of its drug candidates in clinical trials, and the ability to secure regulatory approvals and reimbursement, which could jeopardize commercialization efforts. Additionally, external factors such as competition and shifting investor sentiment toward biotech stocks may further exacerbate the negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares